IPSEF - Ipsen S.A.

Other OTC - Other OTC Delayed price. Currency in USD
117.00
0.00 (0.00%)
At close: 03:47PM EDT
Stock chart is not supported by your current browser
Previous close117.00
Open117.00
Bid0.00 x 0
Ask0.00 x 0
Day's range117.00 - 117.00
52-week range88.50 - 117.00
Volume18
Avg. volume15
Market cap9.911B
Beta (5Y monthly)0.72
PE ratio (TTM)15.31
EPS (TTM)7.64
Earnings dateN/A
Forward dividend & yield1.28 (1.10%)
Ex-dividend date02 Jun 2023
1y target estN/A
  • Globe Newswire

    IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023

    Aggregated presentation by day and by market Name of issuerIdentification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrumentAggregated daily volume (in number of shares) Daily weighted average price of the purchased shares * Market (MIC Code)IPSEN549300M6SGDPB4Z94P1101/06/2023FR0010259150284111,21AQEUIPSEN549300M6SGDPB4Z94P1101/06/2023FR0010259150690111,19CEUXIPSEN549300M6SGDPB4Z94P1101/06/2023FR001025915024111,26TQEXIPSEN549300M6SGDPB4Z94P110

  • Globe Newswire

    Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan

    REGULATED INFORMATION Ipsen initiates a share buy-back programto cover its free employee share-allocation plan Paris (France), 1 June 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 350,000, or about 0.42% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen’s free employee share-allocation plan. This program is

  • Globe Newswire

    Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023

    REGULATED INFORMATION COMBINED SHAREHOLDERS’ MEETING OF IPSEN S.A.HELD ON 31 MAY 2023 ALL THE RESOLUTIONS SUBMITTED TO THE SHAREHOLDERS’ VOTE HAVE BEEN APPROVED Paris (France), 31 May 2023 – The Combined Shareholders’ Meeting of IPSEN S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France), under the chairmanship of Mr. Marc de GARIDEL, Chairman of the Board of Directors and meeting Chairman, and in the presence of

  • Globe Newswire

    Ipsen - Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023

    REGULATED INFORMATION Description of the regulatory framework of the share repurchase programproposed by the Board of Directors to be approved at theCombined Shareholders’ Meeting on 31 May 2023(15th resolution) Boulogne-Billancourt (France), on 31 May 2023 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014, the Delegated Regulation No 2016/1052 of

  • Globe Newswire

    Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

    Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with an estimated prevalence of 1.36 per million individuals and around 900 people diagnosed worldwide.1,2FOP continuously and permanently causes abnormal bone formation,3 leading to progressive mobility loss and shortened life expectancyThere are currently no disease-modifying treatment options available in the E.U.Regulatory processes are continuing

  • Globe Newswire

    Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

    The CRL is related to the U.S. FDA’s previous request for additional information on palovarotene clinical trial dataIpsen anticipates responding to the request in the first quarter of 2023 PARIS, FRANCE, 23 December 2022 – The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation (heterotopic ossification) in people living with fibrodysplasi

  • Globe Newswire

    Cabometyx® in combination with Opdivo® demonstrated continued survival and quality of life benefits with over two years of follow-up in the Phase III CheckMate -9ER trial

    Updated results to be presented at ASCO GU 2022 showed sustained efficacy and tumor shrinkage benefits with Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) compared to sunitinib1People living with advanced renal cell carcinoma treated with the combination continued to report improvements in health-related quality of life2The safety profile at this longer follow-up in the CheckMate -9ER trial was consistent with that previously observed for Cabometyx and Opdivo1 PARIS, FRANCE, 15

  • Globe Newswire

    Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience

    New electronic autoinjector is designed to improve patient experience for people living with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome or acromegalyPerformance and safety studies ongoing, with first launches for the new device expected in 2024A fourth generation Somatuline® Autogel® / Somatuline® Depot device building on Ipsen’s 20 years’ heritage to date PARIS, FRANCE, 16 March 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will invest in a new state-of-the-a

  • Globe Newswire

    Ipsen delivers a strong sales performance in the first quarter of 2022

    Ipsen delivers a strong sales performance in the first quarter of 2022 Paris (France), 27 April 2022 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2022. Highlights A strong first-quarter total-sales performance, with growth of 9.6% at CER [1] (12.5% as reported) to €687.9m, driven by Decapeptyl® (triptorelin), Dysport® (botulinum toxin type A), Cabometyx® (cabozantinib) and Onivyde® (irinotecan lip

  • Globe Newswire

    Ipsen appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

    Paris (France), 16 February 2022 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Catherine Abi-Habib as EVP Strategy, Transformation, and Digital, effective March 1st, 2022. Based in Boulogne-Billancourt, France, she will be reporting directly to David Loew, CEO, Ipsen, and serve on the Executive Leadership Team (ELT). She is replacing Dominique Bery, who after successfully leading the Strategy, Transformation and Digit

  • Globe Newswire

    New patient-reported data demonstrated high satisfaction levels and fewer patients reporting injection-site pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)

    New data presented at ENETS 2022 showed patients treated with Somatuline® Autogel®/Somatline® Depot (lanreotide) pre-filled syringe reported less frequent injection-site pain lasting more than two days than those treated with octreotide long-acting release syringePeople living with gastroenteropancreatic neuroendocrine tumors enrolled on Somatuline® Autogel® patient support programs reported feeling in control and satisfied when administering at-home injections PARIS, France, 8 March 2022 – Ipse

  • Globe Newswire

    Health Canada approves Ipsen’s Sohonos (palovarotene capsules) as the first approved treatment for fibrodysplasia ossificans progressiva

    PARIS, France, 24 January 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the Health Canada approval of Sohonos™ (palovarotene capsules), an oral selective retinoic-acid receptor gamma (RARγ) agonist indicated to reduce the formation of heterotopic ossification (HO; new bone formation) in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva (FOP).1 Sohonos is approved for the treatment of patients with FOP for

  • Globe Newswire

    ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types including metastatic non-small cell lung cancer

    COSMIC-021 Phase Ib study is evaluating Cabometyx® (cabozantinib) in combination with atezolizumab in advanced solid tumors, including non-small cell lung cancerNew analyses from pivotal Phase III Checkmate -9ER trial further support the superior efficacy of Cabometyx and nivolumab over sunitinib in advanced renal cell carcinomaTwo new analyses from pivotal Phase III COSMIC-311 trial further support the potential of Cabometyx in radioactive iodine-refractory differentiated thyroid cancer PARIS,

  • Globe Newswire

    Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury

    Submission based on data from the pivotal international Phase III CONTENT clinical program, also recently published in European Urology1CONTENT showed that Dysport® decreased incontinence episodes, detrusor pressure and increased bladder capacity versus placebo, and improved quality of life1 PARIS, FRANCE, 9 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Dysport® (abobotulinumtoxinA) has received positive opinion in Europe for the management of urinary incontinence (UI) in ad

  • Globe Newswire

    Ipsen delivers strong H1 2022 results and upgrades its full-year guidance

    Paris (France), 28 July 2022 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, presents its financial results for the first half of 2022: H1 2022 financial results Strong sales growth of 10.5% at CER1 (15.2% as reported)Core operating margin of 39.6%; IFRS operating margin of 35.7%Core consolidated net profit of €420m, growing by 19.9%. IFRS net profit up by 30.0% to €394mSolid cash-flow generation and strong balance sheet (€2m closing net debt) Strategic

  • Globe Newswire

    Ipsen announces results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer

    At the primary analysis, the trial did not meet its primary endpoint of overall survival (OS)The safety profile was consistent with previously reported studies of Onivyde® (irinotecan liposomal injection)The clinical study results will be communicated with the regulatory agency PARIS, FRANCE, 03 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III RESILIENT trial did not meet its primary endpoint of overall survival (OS) compared to topotecan. The trial is evaluatin

  • Globe Newswire

    Ipsen and Marengo Therapeutics announce strategic partnership to advance two precision immuno-oncology candidates from Marengo’s STAR Platform into the clinic

    Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation approachIpsen to pay Marengo $45 million upfront with potential for additional milestone payments PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 01 August, 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo Therapeutics, Inc. today announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the

  • Globe Newswire

    Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

    PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at deal close. As part of the transaction, Ipsen acquires Epizyme’s lead medicine, Tazverik® (tazemetostat), a first-i

  • Globe Newswire

    Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

    Six abstracts to be presented demonstrating efficacy and tolerability of investigational Bylvay in select cholestatic liver diseasesNew data emphasizes the consistent benefit of Bylvay as an investigational drug in Alagille syndrome and an approved medicine in PFIC, with evidence of rapid, sustained, and significant improvements in pruritus and sleep, and reductions in serum bile acids (sBAs) Further data shows evidence of disease modification with longer-term native liver survival in PFIC patie

  • Globe Newswire

    Ipsen provides update on Phase III CONTACT-01 trial evaluating cabozantinib in combination with atezolizumab in patients with metastatic non-small cell lung cancer previously treated with immunotherapy and chemotherapy

    The trial did not meet its primary endpoint of overall survival (OS)The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for each single agentThe clinical trial results will be presented at a future medical meeting PARIS, FRANCE, 8 December 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clin

  • Globe Newswire

    Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital - April 2023

    Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)30 April 2023 83,814,526 Gross total* of voting rights: 132,089,350Net total** of

  • Globe Newswire

    Ipsen : 2023 CSM - Formalities for making available preparatory documents to the Meeting

    INFORMATION RELATING TO THE HOLDING OF THE COMBINED SHAREHOLDERS’ MEETING OF 31 MAY 2023 FORMALITIES FOR MAKING AVAILABLE AND CONSULTINGPREPARATORY DOCUMENTS TO THE MEETING Boulogne-Billancourt (France), 10 May 2023 – The Shareholders of the Company are invited to participate in the Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 31 May 2023 at 3:00 p.m. (Paris time) at the Salons de l'Hôtel des Arts et Métiers, 9 bis avenue d'Iéna, 75116 Paris. The pr

  • Globe Newswire

    Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

    Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance Paris (France), 27 April 2023Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the first quarter of 2023. Q1 2023 Q1 2022 % change €m €m Actual CER1 Oncology 570.8 556.4 2.6% 1.1% Neuroscience 156.4 120.2 30.2% 24.4% Rare Disease 14.7 11.3 29.8% 29.0% Total Sales2 741.9 687.9 7.8% 5.7% Highlights Total-sales growth of 5

  • Globe Newswire

    Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

    Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs PARIS, FRANCE, 24 April 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Sandra Silvestri, M.D., Ph.D., as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective 5 May 2023. She will serve on the Executive Leadership Team (ELT) and

  • Globe Newswire

    Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital

    Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)31 March 2023 83,814,526 Gross total* of voting rights: 132,092,083Net total** of